share_log

Forecasting The Future: 4 Analyst Projections For Cue Biopharma

Benzinga ·  Apr 9 10:01

Throughout the last three months, 4 analysts have evaluated Cue Biopharma (NASDAQ:CUE), offering a diverse set of opinions from bullish to bearish.

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings22000
Last 30D11000
1M Ago11000
2M Ago00000
3M Ago00000

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.0, a high estimate of $10.00, and a low estimate of $6.00. This current average has decreased by 7.73% from the previous average price target of $8.67.

price target chart

Investigating Analyst Ratings: An Elaborate Study

A comprehensive examination of how financial experts perceive Cue Biopharma is derived...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment